Pharmalicensing.com: PR Newswire http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us Pharmalicensing.com: PR Newswire http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody NEW YORK, June 24 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) and MRC Technology (MRCT) announced today they have achieved an important milestone through their... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1276 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1276 Tue, 24 Jun 2008 11:00:00 +0000 Valdoxan(R), the First Melatonergic Antidepressant, Receives EU CHMP Positive Opinion for Major Depressive Disorder PARIS, November 21 /PRNewswire/ -- The first melatonergic antidepressant - Valdoxan(R)/Thymanax(R) (agomelatine) - has received a positive opinion from the European Medicines Agency's (EMEA)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2186 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2186 Fri, 21 Nov 2008 16:09:00 +0000 Preterax(R) Prevents and Reverses Renal Disease in Type 2 Diabetics BERLIN, June 16 /PRNewswire/ -- New results of the ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN-MR Controlled Evaluation) trial have been presented today at the European... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1216 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1216 Mon, 16 Jun 2008 15:37:00 +0000 European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients MAIDENHEAD, England, July 7 /PRNewswire/ -- Wyeth Pharmaceuticals, today 3rd July, announced that it has received EMEA marketing approval for Relistor(TM) (methylnaltrexone bromide) subcutaneous... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1356 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1356 Mon, 07 Jul 2008 18:56:00 +0000 Edoxaban - Factor Xa Inhibitor Enters Phase III With Optimal Dose MUNICH, March 27 /PRNewswire/ -- Edoxaban (DU-176b) is a direct Factor Xa inhibitor and is developed to prevent thromboembolic events such as stroke and pulmonary embolism. The Phase II Edoxaban... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2793 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2793 Fri, 27 Mar 2009 11:21:00 +0000